Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb942 · 1 trial · 1 indication
A composite score of ulcerative colitis (UC) disease activity on a scale of increasing severity from 0-9. It is calculated by adding the results from Mayo endoscopic subscore (MES) which measures GI bleeding, stool frequency subscore (SFS) which measures stool frequency per day, and rectal bleeding subscore (RBS), which measures presence of blood during stool passing. Each subscore is a scale of increasing severity from 0 to 3.
| Arm | Type | Description |
|---|---|---|
| Part A: Active drug | ACTIVE_COMPARATOR | Active XmAb942 to be administered to healthy volunteers. Single administration of 3 ascending dose (SAD) levels of XmAb942 via SC (3 cohorts) or IV (3 cohorts) administration in 8 participants per cohort, randomized in a 3:1 ratio to active or placebo. |
| Part A: Placebo | PLACEBO_COMPARATOR | Placebo Comparator to be administered to healthy volunteers. Single administration of 3 ascending dose (SAD) levels will be randomized in a 3:1 ratio to active or placebo. |
| Part B: Active | ACTIVE_COMPARATOR | Active XmAb942 to be administered to healthy volunteers. Multiple administrations of 2 ascending dose (MAD) levels of XmAb942 via IV administration in 8 participants per cohort, randomized in a 3:1 ratio to active or placebo. |
| Part B: Placebo | PLACEBO_COMPARATOR | Placebo Comparator to be administered to healthy volunteers. Multiple administrations of 2 ascending dose (MAD) levels will be randomized in a 3:1 ratio to active or placebo. |
| Part C: Active | ACTIVE_COMPARATOR | Active XmAb942 to be administered to participants with moderately to severely active Ulcerative Colitis |
| Part C: placebo | PLACEBO_COMPARATOR | Placebo comparator to be administered to participants with moderately to severely active Ulcerative Colitis |
| Name | Type | Description |
|---|---|---|
| XmAb942 | BIOLOGICAL | Antibody |
| Placebo | DRUG | Placebo |
Inclusion Criteria: Parts A and B * Age 18-55 * Must be in good health with no significant medical history * Clinical laboratory values within normal range * BMI 18-35 (inclusive) * Contraceptive use by men or women consistent with local regulations * Able and willing to provide written informed c...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
XmAb942 is an investigational monoclonal antibody being developed for the treatment of Ulcerative Colitis (UC). It is currently in Phase 1 clinical development, with a study enrolling healthy participants and those with UC to evaluate its safety and efficacy.
XmAb942 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy participants and individuals with Ulcerative Colitis.
XmAb942 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 trial is currently recruiting participants to assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers and patients with Ulcerative Colitis.
XmAb942 is being studied in a single Phase 1 clinical trial with the identifier NCT06619990. This randomized, double-blind, placebo-controlled study is recruiting approximately 270 participants across multiple countries, including the United States, Argentina, Australia, Brazil, Bulgaria, Canada, and others.
No alternative names for XmAb942 have been reported. The drug is identified solely by its code name XmAb942 in clinical trial registries and by its developer, Xencor, Inc. It is a distinct investigational monoclonal antibody being evaluated for Ulcerative Colitis.